semaglutide for heart GLP-1 agonists like Ozempic may reduce cardiovascular events by 20% Semaglutide Reduces Need for Diuretics

MC1R agonism clearly drives melanogenesis, and MC4R agonism clearly suppresses appetite

(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority

S., Bhatnagar, A

Shut off food noise and quiet cravings Reduce hunger and feel full longer Improve metabolic efficiency Safe, effective, and clinically guided Care guided by licensed medical professionals

These drugs are prescribed according to the needs of each patient and are authorized for particular indications